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A compelling body of non-randomized evidence has showed 
that SBRT is a safe and efficient way to control multiple 
metastatic sites. However, when treating metastatic patients 
(even if “oligometastatic”), selection criteria are a pivotal 
issue. In general, clinical indications are the same as those 
for metastasectomy (pulmonary and/or liver 
metastasectomy), but without the limits regarding patients 
unfit for surgery. 
Current literature has showed promising long-term survival 
outcomes after SBRT for limited metastases. Future studies 
are, and will be, addressing: 1) what (if any) benefit SBRT 
(and other local therapies) should offer for patients with 
limited metastases, 2) which patients are most likely to 
benefit from SBRT (host-related factors underlying the 
oligometastatic state, i.e. miRNA), 3) optimal dose and 
fractionation schedules, 4) what radiobiologic mechanisms 
are relevant in the treatment of the target tumor (i.e., SBRT 
as “immunomodulator”). 
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Standard treatment of metastatic cancer is systemic 
therapies. Local treatments for oligometastatic patients may 
have significant role since a large majority of patients 
treated with systemic chemotherapy experience progression 
mostly in initial sites of tumor burden rather than new sites 
of progression. Surgical excision of metastatic sites usually 
from liver and lung that have been shown to prolong survival 
in colorectal cancer, sarcomas, melanoma, breast cancer and 
many other tumor types.  
Currently surgery is considered to be standard approach for 
these groups of patients. Surgical series of hepatic 
metastasectomy of primary colorectal cancer resulted 18-51 
% 5-year survival rate with 2-7% operative mortality and 6-13 
% serious morbidity risk. Most of the metastasectomy data 
are based on single institutional series and had many 
confounding factors such as patient selection that cause 
some doubts about the results. It should also be considered 
that many tumors are inoperable due to tumor location or 
medical inoperability of the patient. 
Stereotactic treatment was developed by a neurosurgeon Lars 
Leksell to treat inoperable deeply seated lesions in the brain. 
SABR recently become popular to extra-cranial sites with 
technological improvements. Its strengths include high rates 
of tumor eradication via non-invasive, convenient, short 
outpatient treatment course, favorable toxicity and no 
recovery time. It yielded very good results for treatment of 
primary and metastatic tumors in various body sites in 
properly selected patients. However despite potential 
advantages, there are few published retrospective or phase II 
studies with limited patient number. These studies about 
metastatic liver disease that have been treated with SABR 
yielded 70-82 % 2-year local control rate without any serious 
toxicity. So there is great hope that SABR may find prominent 
place in treatment of metastatic cancer. There are also few 
literature data with favorable results on lung, adrenal, lymph 
node metastasis treated with SABR. 
There is no randomized study comparing efficacy and toxicity 
of surgery and SABR in oligometastatic setting. Many authors 
consider surgery as the standard treatment for local 
management of metastatic sites. However, SABR is promising 
approach as a complementary or alternative regimen to 
surgery. Until well-designed randomized studies comparing 
these two regimens, selection of treatment should be 
individualized to the patient with the guidance of available 
data. 
Individualization of treatment is dependent on patient 
factors and metastatic sites. Performance status, 
comorbidities of the patient, location and number of 
metastatic sites, previous treatments, underlying prognosis, 
tumor biology and experience of the team are all important 
factors for consideration of local treatment.  
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Purpose/Objective: To assess the safety and efficacy of 
stereotactic body radiotherapy (SBRT) in patients affected by 
inoperable locally advanced pancreatic adenocarcinoma and 
local recurrence after surgery. 
Materials and Methods: Patients with unresectable locally 
advanced tumor or local recurrence disease were treated 
with exclusive SBRT. All cases were evaluated by 
multidisciplinary team. Irradiated lesions had a diameter less 
than 5 cm and no metastatic disease was present at the time 
of SBRT. Prescription dose was 45 Gy in 6 daily fractions of 
7.5 Gy. SBRT was delivered using the volumetric modulated 
arc therapy (VMAT) by RapidArc technique. Primary end-point 
was freedom from local progressions (FFLP) and secondary 
end-points were overall survival (OS) and toxicity. Local 
control was defined according to RECIST criteria. Acute and 
late toxicity was scored according to the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0. 
Results: Between January 2010 and October 2012, 62 
patients were treated. Forty five patients (74%) had 
unresectable locally advanced disease and 17 patients (26%) 
had local recurrence after surgery. Median follow-up was 12 
months (3 – 48 months). Nineteen (30%) patients were alive 
at the time of analysis. Median follow-up was 17 months in 
this group of patients (range 12–48 months). In patients with 
inoperable locally advanced disease, FFLP was 90% at 1year. 
Median progression free-survival was 8 months. Median OS 
was 13 months, with 1-year OS rate of 51%. Ca 19.9 value 
increased in 28 cases (62% of this subgroup) and Ca 19.9 
value was less than 300 U/ml in 12 patients (43%) while it 
was more than 300 U/ml in 16 patients (57%). Univariate 
analysis showed that Ca 19.9 < 300 U/ml was closely 
correlated (p = .055) to a better OS. In those patients with 
local recurrence after surgery, FFLP was 85% at median 
follow-up. Median progression free-survival was 9 months. 
Median OS was 19 months, with 1-year OS rate of 53%. In all 
the cases, toxicity rates were satisfactory with no patients 
who experienced acute grade 3 toxicity or greater. 
Conclusions: SBRT is a safe and efficacy treatment to 
improve local control in patients with unresectable locally 
advanced or recurrence pancreatic adenocarcinoma, in 
absence of grade 3 toxicity or greater. Our results suggest 
that SBRT may be a promising therapeutic option in the 
multi-modality treatment of these patients.  
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Purpose/Objective: Treatment planning for Stereotactic 
Body Radiation Therapy (SBRT) of liver tumours is often 
challenging due to large respiratory motion and a close 
vicinity of OARs such as great vessels and duodenum. In such 
cases a section of the PTV is edited to spare nearby OARs. We 
evaluated a PTV-less probabilistic planning technique which 
directly incorporates respiratory motion and other geometric 
uncertainties of the GTV in the dose optimization process. An 
improved balance between OAR exposure and the confidence 
of proper target dosage is expected, as well as a more 
efficient planning procedure since less human interaction is 
required. 
Materials and Methods: Four liver SBRT plans (3x20 Gy 
prescription) for which clinical planning had been 
problematic due to OAR constraints were re-planned using an 
in-house developed research plug-in for Pinnacle (version 
9.100). The plug-in combines the tumour trajectory extracted 
from the 4D planning CT (~1 cm amplitude for this case) with 
the Gaussian distribution of random errors (0.25 cm) into a 
dose blurring kernel, and incorporates a Gaussian distribution 
of systematic errors as GTV offsets (0.34 cm). Our 
probabilistic objective assumes shift invariance and aims for 
a set confidence (e.g. 90%) of GTV minimum dose. Clinical 
and probabilistic plans were compared using in-house 
software that accurately simulates the effects of motion and 
uncertainties on an optimized dose distribution by explicitly 
sampling three daily errors for each systematic error (10000 
were simulated), and 100 positions along the breathing 
trajectory for each daily error. OARs were evaluated via a 
traditional DVH. 
Results: In three out of four cases the probabilistic plan 
showed a clear clinical benefit compared to the conventional 
plan. In two cases the clinical PTV coverage was lowered to 
spare the great vessels and duodenum, here probabilistic 
planning significantly increases GTV coverage, while 
maintaining a low enough dose on the OAR (e.g. Fig. 1). In a 
third case a higher dose to the great vessels was tolerated in 
the clinical plan in favour of getting proper PTV coverage. 
Using probabilistic planning we were able to reduce the great 
vessel dose while still reaching 90% target dose confidence. 
In the fourth case all clinical constraints were met both in 
the clinical and probabilistic plan. 
Conclusions: Probabilistic planning can make a valuable 
contribution to treatment planning in those cases in which it 
is difficult to meet all clinical criteria. 
 
Figure 1. Isodose lines for a clinical (left) and probabilistic 
(right) plan. Due to the overlap of the duodenum (blue) with 
the PTV (pink line), clinical optimization was done only on 
the dashed part of the PTV, leading to reduced GTV dose 
confidence (99% of the volume received 87.5% of the dose 
with a probability of 90%). Probabilistic planning did not use 
a PTV, and led to sufficient GTV coverage (99% of the volume 
received 95% of the dose with a probability of 90%) while 
still sparing the duodenum.  
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Purpose/Objective: Stereotactic body radiation therapy 
(SBRT) is becoming the standard of care for early stage lung 
cancer patients. Toxicity data of lung injury after SBRT 
remains sparse. Our work evaluated toxicity by analyzing lung 
density changes for lung cancer patients that underwent 
SBRT. 
Materials and Methods: From 2003 to 2009, 63 patients 
received SBRT treatments in 3-5 fractions for a total median 
dose of 54Gy (range 30-60Gy). RT-induced lung density 
changes were evaluated after registration of the planning CT 
with post-RT CT scans acquired at 3, 6, 12, 18, and 24 
months after treatment. A comprehensive dose-response 
analysis was performed including 1) CT number (HU) changes 
as a function of dose, 2) spatial analysis of lung fibrosis 
location, and 3) correlation of lung tissue changes with 
clinical end-points. We generated patient specific dose-
response curves (DRC) by binning voxels into 10Gy dose bins, 
calculating the average HU for each dose bin, and evaluating 
the HU change as a function of dose. Spatial analysis was 
performed by contouring regions of fibrosis and analyzing the 
centroid movement of the fibrosis volume relative to the 
gross tumor volume (GTV) centroid. Airway or vessel 
branches inside the lung were paired on the pre- and post-RT 
scans to guide the spline based deformable registration of 
the lung. Regional density increases were classified as local 
lung collapse or fibrotic based on the local volume changes 
calculated using the deformation field Jacobian. 
Results: DRCs exhibited a linear HU increase up to 35Gy and 
a plateau beyond 35Gy. The response of the 4-5fx (high 
toxicity risk) and 3fx (lower toxicity risk) groups were notably 
different as the 4-5fx group experienced HU changes twice 
the increase seen in the 3fx group. The average radial 
movement of fibrosis centroids relative to the GTV centroids 
was 2.6 cm with movement greater than 5 cm occurring in 
11% of patients questioning the direct exposure of the 
fibrotic tissues to high doses. 30% of patients with a large 
fibrotic tissue displacement showed concurrent local lung 
volume contraction (according to the Jacobian) compatible 
with radiation-induced regional lung collapse.  
Conclusions: The current study presents a comprehensive 
dosimetric, spatial, and clinical analysis of lung density 
changes after SBRT. In addition to characterizing dose 
response after SBRT, we demonstrate certain unexpected 
observations including a dose-response plateau at 35Gy and 
fibrosis volume travel outside of the high dose region. Our 
clinical analysis suggests some of these abnormalities may be 
explained by regional lung collapse due to high SBRT doses to 
the proximal airways. Although current clinical toxicity rates 
with SBRT are low, as treatments become more aggressive, 
toxicity rates will increase and better prediction of lung 
response will be needed. Our work presents important data 
towards the mechanical and clinical understanding of lung 
injury after SBRT.  
   
 
